The Ever-Escalating Cost of Cancer Drugs

June 22016The Ever-Escalating Cost of Cancer Drugs

The total cost of oncology drugs and supportive care medications surged 11.5 percent in 2015 to reach $107 billion globally, according to a new study from IMS Institute for Healthcare Informatics. The spending is based on invoice prices, the amount hospitals or pharmacies paid to distributors. The challenge: how do patients and safety-net providers pay for the escalating price to treat cancer. Certain strategies to leverage drug class of trade, regulatory programs, or targeted populations for treatment can be engaged, but it's difficult to envision a long-term solution if the current increased cost trajectory continues.

Read More